Activation of angiotensin-converting enzyme 2 improves cardiac electrical changes in ventricular repolarization in streptozotocin-induced hyperglycaemic rats

Europace

Volumn 16, Issue 11, 2014, Pages 1689-1696

  Coutinho, Danielle C O ^a   Monnerat Cahli, Gustavo ^b   Ferreira, Anderson J ^a   Medei, Emiliano ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

ACE2; Angiotensin (1 7); Cardiac electrophysiology; Diabetes; Diminazene aceturate; Hyperglycaemia

Indexed keywords

DIMINAZENE ACETURATE; SODIUM CHLORIDE; STREPTOZOCIN; ANGIOTENSIN CONVERTING ENZYME 2; ANTIARRHYTHMIC AGENT; DIMINAZENE; DIPEPTIDYL CARBOXYPEPTIDASE; ENZYME ACTIVATOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ELECTRIC ACTIVITY; ELECTROCARDIOGRAM; ENZYME ACTIVATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART PACING; HEART REPOLARIZATION; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; QRS COMPLEX; RAT; TREATMENT OUTCOME; WEIGHT REDUCTION; ACTION POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; ARRHYTHMIAS, CARDIAC; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; HEART VENTRICLE; METABOLISM; PATHOPHYSIOLOGY; TIME; WISTAR RAT;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; DIMINAZENE; ENZYME ACTIVATION; ENZYME ACTIVATORS; HEART CONDUCTION SYSTEM; HEART RATE; HEART VENTRICLES; HYPERGLYCEMIA; MALE; PEPTIDYL-DIPEPTIDASE A; RATS, WISTAR; STREPTOZOCIN; TIME FACTORS;

EID: 84912011244     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euu070     Document Type: Article

References (43)

1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, HowardBV et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.
2. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974; 23:105-11.
3. Kahn JK, Sisson JC, Vinik AI. QT interval prolongation and sudden cardiac death in diabetic autonomic neuropathy. J Clin Endocrinol Metab 1987;64:751-4.
4. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115:387-97.
5. Murc a TM,Almeida TCS,Raizada MK,Ferreira AJ. Chronic activation of endogenous angiotensin-converting enzyme 2 protects diabetic rats from cardiovascular autonomic dysfunction. Exp Physiol 2012, 97, 699-709.
6. Dhalla NS, Liu X, Panagia V, Takeda N. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 1998;40:239-47.
7. Murç a TM, Moraes PL, Capuruço CA, Santos CH, Melo MB, Santos RAS et al. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Reg Pep 2012;177:107-15.
8. An D, Rod rigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006;291:H1489-506.
9. Cassis O, Gallego M, Iriarte M, Sánchez-Chapula JA. Effects of diabetic cardiomyopathyon regional electrophysiologic characteristics of rat ventricle. Diabetologia 2000; 43:101-9.
10. Magyar J, Ruszná k Z, Szentesi P, Szûcs G, Ková cs L. Action potentials and potassium currents in rat ventricular muscle during experimental diabetes. J Mol Cell Cardiol 1992;24:841-53.
11. Arildsen H, May O, Christiansen EH, Damsgaard EM. Increased QT dispersion in patients with insulin-dependent diabetes mellitus. Int J Cardiol 1999;71:235-42.
12. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.
13. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano Net al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2 000;87:E1-9.
14. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypepti dase. J Biol Chem 2000;275:33238-43.
15. Santos RAS, Simo? es e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I et al. Angiotensin-(1- 7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003;100:8258-63.
16. Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga S et al. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 2013;112:1104-11.
17. Santos SH, Giani JF, Burghi V, Miquet JG, Qadri F, Braga JF et al. Oral administration of angiotens in-(1-7) ameliorates type 2 diabetes in rats. J Mol Med 2014;92:255-65.
18. Kulemina LV, Ostrov DA. Prediction of off-target effects on angiotensin-converting enzyme 2. J Biomol Screen 2011;16:878-85.
19. Qi Y, Zhang J, Cole-Jeffrey CT, Shenoy V, Espejo A, Hanna M, Song C et al. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension 2013;62:746-52.
20. Sharma V, Sharma A, Saran V, Bernatchez PN, Allard MF, McNeill JH. b-receptor antagonist treatment prevents activation of cell death signaling in the diabetic heart independent of its metabolic actions. Eur J Pharmacol 2011;657:117-25.
21. Foureaux G, Nogueira JC, Nogueira BS, Fulgêncio GO, Menezes GB, Fernandes SO et al. Antiglaucomatous effects of the activation of intrinsic angiotensin-converting enzyme 2. Invest Ophthalmol Vis Sci 2013;54:4296-306.
22. Medei E, Marocolo M, Rodrigues Dde C, Arantes PC, Takiya CM, Silva J et al. Chronic treatment with anabolic stero ids induces ventricular repolarization disturbances: cellular, ionic and molecular mechanism. J Mol Cell Cardiol 2010;49:165-75.
23. GuoD, Zhao X,WuY, LiuT,Kowey PR, YanGX. L-type calcium current reacti vation contributes to arrhythmogenesis associated with action potential triangulation. J Cardiovasc Electrophysiol 2007;18:196-203.
24. Hondeghem LM, Carlsson L, Duker G. Instability and triangulatio n of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001;103:2004-13.
25. Pueyo E,Husti Z,Hornyik T,Baczkó I,Laguna P,Varró A,et al. Mechanisms of ventricular rate adaptation as a predictor of arrhythmic risk. Am J Physiol Heart Circ Physiol 2010, 298:H1577-87.
26. Ferreira AJ, Shenoy V, Qi Y, Fraga-S ilva RA, Santos RAS, Katovich MJ et al. Angiotensin converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 2011;96: 287-94.
27. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Re spir Crit Care Med 2009;179:1048-54.
28. Fraga-Silva RA, Sorg BS,Wankhede M, DeDeugd C, Jun JY, Baker MB et al. ACE2 activation promotes antithrombotic activity. Mol Med 2010;16:210-5.
29. Fraga-Silva RA, Costa-Fraga FP, Murça TM, Moraes PL, Martins Lima A, Lautner RQ et al. Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension 201 3;61:1233-8.
30. Mecca AP, Regenhardt RW, O'Connor TE, Joseph JP, Raizada MK, Katovich MJ, Sumners C. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol 2011;96:1084-96.
31. ShenoyV, Gjymishka A, Jarajapu YP,QiY, Afzal A, RigattoK et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med 2013;187:648-57.
32. Rigatto K, Casali KR, Shenoy V, Katovich MJ, Raizada MK. Diminazene aceturate improves autonomic modulation in pulmonary hypertension. Eur J Pharmacol 2013;713:89-93.
33. Tikellis C, Pickering R, Tsorotes D, Du XJ, Kiriazis H, Nguyen-Huu TP et al. Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. Cli n Sci (Lond) 2012;123:519-29.
34. Jarajapu YP, Bhatwadekar AD, Caballero S, Hazra S, Shenoy V, Medina R et al. Activation of the ACE2/angiotensin-(1-7)/Mas receptor axis enhances the repa rative function of dysfunctional diabetic endothelial progenitors. Diabetes 2013;62: 1258-69.
35. PanCH, Lin JL, Lai LP, Chen CL, Stephen Huang SK, Lin CS. Downregulation of angiotensin conv erting enzyme II is associated with pacing-induced sustained atrial fibrillation. FEBS Lett 2007;581:526-34.
36. Bevilaqua ER, Kushmerick C, Beira?o PS, Naves LA. Angiotensin 1-7 increases quanta l content and facilitation at the frog neuromuscular junction. Brain Res 2002; 927:208-11.
37. Ferreira AJ, Santos RAS, Almeida AP. Angiotensin-(1- 7): Cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001;38:665-8.
38. Ferreira AJ, Moraes PL, Foureaux G, Andrade AB, Santos RAS, Almeida AP. The angiotensin-(1-7)/Mas receptor axis is expressed in sinoatria l node cells of rats. J Histochem Cytochem 2011;59:761-8.
39. De Mello WC. Angiotensin (1 - 7) re-establishes impulse conduction in cardiac muscle during ischaemia-reperfusion. The role of the sodiumpump. J Renin Angiotensin Aldosterone Syst 2004;5:203-8.
40. Liao X,Wang L, Yang C, He J,Wang X, Guo R et al. Cyclooxygenase mediates cardioprotection of angiotensin-(1-7) against ischemia/reperfusion-induced injury through the inhibition of oxidative stress. Mol Med Rep 2011;4:1145-50.
41. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE et al. Angio tensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002;417:822-8.
42. Nakamura K, Koibuchi N, Nishimatsu H, Higashikuni Y, Hirata Y, Kugiyama K et al. Can desartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice. Hypertens Res 2008;31:1953-61.
43. Bernardi S, Burns WC, Toffoli B, Pickering R, Sakoda M, Tsorotes D et al. Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin-(1-7). Clin Sci 2012;123:29-37.